TOKYO, Apr 07 (Pulse News Wire) – HEALIOS K.K. (4593.T) signed a contract with JENECELL Co.
To supply cultured supernatants for cosmetic raw materials. Under the agreement, HEALIOS will initially deliver products worth 1 billion yen, with subsequent shipments scheduled from July 2026 onwards. The contract includes ongoing supply commitments agreed upon with JENECELL. JENECELL, based in Seoul, specializes in developing innovative products using stem cell technology across various fields such as pharmaceuticals, medical devices, and cosmetics.
Founded in September 2025, JENECELL currently has a capital of 3,000,000,000 won and employs seven people. Under the agreement, HEALIOS expects revenue recognition beginning in the third quarter of its fiscal year ending December 2026. The initial shipment's sales will be disclosed once confirmed. HEALIOS will promptly inform stakeholders of any further significant developments related to this contract.
🟢 Confidence: High AI-translated content.